Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer

Background: Oncolytic viral therapy is a new strategy for tumor eradication which combines the advantages of viral therapy and gene therapy. Silencing SATB1 exhibits strong inhibitory effect on the growth of prostate cancer. Docetaxel (DTX) is the gold standard for chemotherapy of prostate cancer, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Lijun, Yu, Haiyuan, Ma, Sai, Xu, Ziyang, Wei, Fukun, Yang, Chunhua, Zheng, Junnian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890306/
https://www.ncbi.nlm.nih.gov/pubmed/33613773
http://dx.doi.org/10.7150/jca.46868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890306/
https://www.ncbi.nlm.nih.gov/pubmed/33613773
http://dx.doi.org/10.7150/jca.46868

Ejemplares similares